3,4-dipropoxybenzoic acid | 794582-28-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-dipropoxybenzoic acid
• 英文别名: 3,4-dipropoxy-benzoic acid；3,4-Dipropoxy-benzoesaeure；3,4-di-propoxybenzoic acid
• CAS: 794582-28-8
• 化学式: C₁₃H₁₈O₄
• mdl: MFCD06368058
• 分子量: 238.284
• InChiKey: KVGLIDHZBWTUQL-UHFFFAOYSA-N

物化性质

• 熔点：
  157 °C
• 沸点：
  358.2±22.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-dipropoxybenzoic acid 在 硝酸 、 溶剂黄146 作用下， 以27%的产率得到2-nitro-4,5-dipropoxybenzoic acid
  参考文献：
  名称：

  Lipoprotein Signal Peptidase Inhibitors with Antibiotic Properties Identified through Design of a Robust In Vitro HT Platform

  摘要：

  As resistance to antibiotics increases, the exploration of new targets and strategies to combat pathogenic bacteria becomes more urgent. Ideal protein targets are required for viability across many species, are unique to prokaryotes to limit effects on the host, and have robust assays to quantitate activity and identify inhibitors. Lipoprotein signal peptidase (Lsp) is a transmembrane aspartyl protease required for lipoprotein maturation and comprehensively fits these criteria. Here, we have developed the first in vitro high-throughput assay to monitor proteolysis by Lsp. We employed our high-throughput screen assay against 646,275 compounds to discover inhibitors of Lsp and synthesized a range of analogs to generate molecules with nanomolar half maximal inhibitory concentration values. Importantly, our inhibitors are effective in preventing the growth of E. coli cultures in the presence of outermembrane permeabilizer PMBN and should facilitate development of antibacterial agents with a novel mechanism of action to treat antibiotic-resistant bacteria.

  DOI：

  10.1016/j.chembiol.2017.12.011
• 作为产物：
  描述：

  4-(3,4-dipropoxy-phenyl)-4-oxo-butyric acid 在 potassium permanganate 作用下， 生成 3,4-dipropoxybenzoic acid
  参考文献：
  名称：

  Irani et al., Journal of the University of Bombay, Science: Physical Sciences, Mathematics, Biological Sciences and Medicine, 1950, vol. 18/5 A, p. 1,4

  摘要：

  DOI：

文献信息

• The synthesis and mesomorphism of di-, tetra- and hexa-catenar liquid crystals based on 2,2′-bipyridine
  作者：Kathryn E. Rowe、Duncan W. Bruce

  DOI：10.1039/a706400d

  日期：——

  2,2′-Bipyridines are known to coordinate to a wide variety of metal centres. In this paper, liquid-crystalline two-chained (dicatenar), four-chained (tetracatenar) and six-chained (hexacatenar) bipyridines are synthesised and their mesomorphism is described. For the tetracatenar bipyridines, a full homologous series, from tetramethoxy to tetratetradecyloxy, was synthesised, and the phase diagram showed a classic progression from nematic and smectic C phases at short chain length, through a cubic phase to a columnar phase.

  2,2'-联吡啶已知可与多种金属中心配位。本文合成了液晶态的二链（二联）、四链（四联）和六链（六联）联吡啶，并描述了它们的介晶性质。对于四联联吡啶，合成了一系列完整的同系物，从四甲氧基到四十四烷氧基，相图显示了从短链长度的向列相和近晶C相，经过立方相到柱状相的经典演化过程。
• [EN] S1P RECEPTORS MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010042998A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

  该发明涉及具有S1P受体调节活性的新化合物，最好具有对癌细胞和其他细胞类型具有凋亡活性和/或抗增殖活性。此外，该发明涉及包含该发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如癌症。该发明的另一个方面涉及使用包含该发明中至少一种化合物的药物制备药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如癌症。
• Combinatorial synthesis of isoxazole library and their liquid crystalline properties
  作者：Masahiro Tanaka、Takeharu Haino、Keiko Ideta、Kanji Kubo、Akira Mori、Yoshimasa Fukazawa

  DOI：10.1016/j.tet.2006.11.005

  日期：2007.1

  on solid support in a parallel fashion. Highly regioselective 1,3-dipolar cycloaddition of the nitrile oxides to the triple bond of the solid-attached ethynylbenzamides gave isoxazoles on solid support in good yield. Thirty molecules of them exhibited mesomorphic properties. The combination of molecular mechanics calculations and X-ray diffraction experiments of 2g and 3g revealed that the smectic phase

  在固体支持物上通过组合合成以平行方式合成了六种类型的包括60个分子的异恶唑。腈氧化物对与固体连接的乙炔基苯甲酰胺的三键的高度区域选择性的1，3-偶极环加成反应以良好收率得到了在固体载体上的异恶唑。它们的三十个分子表现出介晶性质。分子力学计算和X射线衍射实验的组合2克和3克揭示的近晶相2克有双层结构，而3克呈单层液晶相。与2g和3g的单晶结构相比，它们得到了支持。
• Hydroxamic Acid Derivatives and the Preparation Method Thereof
  申请人：Rho Ho Sik

  公开号：US20080242730A1

  公开（公告）日：2008-10-02

  The present invention provides hydroxamic acid derivatives represented by the formula, having antioxidation, collagen biosynthesis promotion and skin pore contraction effects, and a method for preparation thereof. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula as an active ingredient.

  本发明提供了由以下式表示的羟羧胺酸衍生物，具有抗氧化、胶原蛋白合成促进和皮肤毛孔收缩效果，以及其制备方法。此外，本发明提供了用作预防皮肤衰老的护肤外用组合物，含有上述由该式表示的羟羧胺酸衍生物作为活性成分。
• Studies on Synthesis and Structure-Activity Relationship (SAR) of Derivatives of a New Natural Product from Marine Fungi as Inhibitors of Influenza Virus Neuraminidase
  作者：Jing Li、Dingmei Zhang、Xun Zhu、Zhenjian He、Shu Liu、Mengfeng Li、Jiyan Pang、Yongcheng Lin

  DOI：10.3390/md9101887

  日期：——

  non-nitrogenous aromatic ether Neuraminidase (NA) inhibitors. Their structures are simple and the synthesis routes are not complex. The structure-activity relationship (SAR) analysis revealed that the aryl aldehyde and unsubstituted hydroxyl were important to NA inhibitory activities. Molecular docking studies were carried out to explain the SAR of the compounds, and provided valuable information for further

  基于来自红树林真菌的天然异戊二烯苯基醚，合成了 32 种类似物并评估了其对流感 H1N1 神经氨酸酶的抑制活性。化合物 15 (3-(烯丙氧基)-4-羟基苯甲醛) 表现出最有效的抑制活性，A/GuangdongSB/01/2009 (H1N1) 的 IC(50) 值为 26.96 μM，A/Guangdong/03/ 为 27.73 μM 2009 (H1N1) 和 A/Guangdong/05/2009 (H1N1) 分别为 25.13 μM，比苯甲酸衍生物强（~mM 水平）。这是一种新型的非含氮芳香醚神经氨酸酶（NA）抑制剂。它们的结构简单，合成路线并不复杂。构效关系（SAR）分析表明芳醛和未取代的羟基对NA抑制活性很重要。